Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201207097 Principal Investigator: Govindan, Ramaswamy
Title: An open-label, Phase I, dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY 1000394 given in a 3 days on / 4 days off schedule in subjects with advanced malignancies
Phase: I Disease Site: Multiple Sites
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The objective of this study is to establish that the medication BAY100094 is safe to use and to find out what the best dose is for patients with cancer.
 
More Information:
ClinicalTrials.Gov Link
Internal Protocol Documents (requires Siteman administrative database password)